News & Updates

Show Multimedia Only

Icosabutate shows potential as treatment for MASH

24 Aug 2025

Treatment with icosabutate is associated with encouraging fibrosis and noninvasive biomarker data, lending support for its development in patients with metabolic dysfunction-associated steatohepatitis (MASH), reports a study.

Icosabutate shows potential as treatment for MASH

24 Aug 2025

First-line antiseizure medications equally effective in routine paediatric care

23 Aug 2025

In the first-line treatment of newly diagnosed childhood epilepsy, antiseizure medications (ASMs) such as oxcarbazepine, valproate, levetiracetam, topiramate, and lamotrigine perform similarly, with no notable difference in outcomes, according to a retrospective cohort study.

First-line antiseizure medications equally effective in routine paediatric care

23 Aug 2025

Navepegritide tied to increased growth velocity in children with ACH

23 Aug 2025 by

Once-weekly treatment with navepegritide was associated with significantly improved annualized growth velocity (AGV) in children with achondroplasia (ACH) compared with placebo, according to results from the pivotal ApproaCH trial presented at ENDO 2025.

Navepegritide tied to increased growth velocity in children with ACH

23 Aug 2025

Several factors tied to treatment failure in children starting first-line ART

22 Aug 2025 by

In children living with HIV initiating antiretroviral therapy (ART), factors such as the ART regimen, age, BMI, and baseline CD4 count, among others, can predict treatment failure, according to a study.

Several factors tied to treatment failure in children starting first-line ART

22 Aug 2025

Third-line secukinumab tied to reduced survival in axSpA, axPsA

22 Aug 2025 by

A real-word study in Argentina has found poor access to secukinumab treatment among patients with public health insurance than those using the social security system or private health coverage. Furthermore, use of secukinumab as third-line therapy or higher is associated with less survival.

Third-line secukinumab tied to reduced survival in axSpA, axPsA

22 Aug 2025

$Vedolizumab–tofacitinib combo induces response in refractory UC$

Vedolizumab–tofacitinib combo induces response in refractory UC

22 Aug 2025

Patients with ulcerative colitis (UC) refractory to anti-TNF and second-line therapies appear to benefit from combination therapy with vedolizumab plus tofacitinib, with many of them achieving clinical remission, as shown in a study.

Vedolizumab–tofacitinib combo induces response in refractory UC

22 Aug 2025

Novel once-weekly oral ART regimen scores high for viral suppression maintenance

21 Aug 2025 by

A once-weekly oral antiretroviral therapy (ART) regimen combining the nucleoside reverse transcriptase translocation inhibitor (NRTTI) islatravir with the non-nucleoside reverse transcriptase inhibitor (NNRTI) ulonivirine helps maintain viral suppression in adults living with HIV-1, according to a phase IIb study.

Novel once-weekly oral ART regimen scores high for viral suppression maintenance

21 Aug 2025

Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women

21 Aug 2025 by

In postmenopausal women with overweight or obesity, the use of tirzepatide alongside menopause hormone therapy appears to yield better weight loss outcomes than treating with tirzepatide alone, findings from a real-world analysis have shown.

Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women

21 Aug 2025

Novel selective OX2R antagonist works well for people with insomnia

20 Aug 2025 by

The novel selective orexin-2 receptor (OX2R) antagonist seltorexant helped promote sleep in people with insomnia, with the efficacy maintained over a 2-week treatment period, according to a phase 2b study.

Novel selective OX2R antagonist works well for people with insomnia

20 Aug 2025

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

20 Aug 2025 by

Patients with postbariatric hypoglycaemia (PBH) may benefit from using mizagliflozin, which contributes to significant reductions in hypoglycaemic events, reports a study presented at ENDO 2025.

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

20 Aug 2025

News & Updates

Filter by Specialty:

Specialty:

Icosabutate shows potential as treatment for MASH

Icosabutate shows potential as treatment for MASH

First-line antiseizure medications equally effective in routine paediatric care

First-line antiseizure medications equally effective in routine paediatric care

Navepegritide tied to increased growth velocity in children with ACH

Navepegritide tied to increased growth velocity in children with ACH

Several factors tied to treatment failure in children starting first-line ART

Several factors tied to treatment failure in children starting first-line ART

Third-line secukinumab tied to reduced survival in axSpA, axPsA

Third-line secukinumab tied to reduced survival in axSpA, axPsA

Vedolizumab–tofacitinib combo induces response in refractory UC

Vedolizumab–tofacitinib combo induces response in refractory UC

Novel once-weekly oral ART regimen scores high for viral suppression maintenance

Novel once-weekly oral ART regimen scores high for viral suppression maintenance

Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women

Real-world data support tirzepatide + hormone therapy for weight loss in postmenopausal women

Novel selective OX2R antagonist works well for people with insomnia

Novel selective OX2R antagonist works well for people with insomnia

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia

Mizagliflozin improves postprandial glucose in postbariatric hypoglycaemia